Management of Alcohol Withdrawal and Promoting Abstinence in Patients with Liver Dysfunction

Alcohol Withdrawal Management

The American Association for the Study of Liver Diseases recommends lorazepam as the preferred benzodiazepine for managing alcohol withdrawal syndrome in patients with liver dysfunction, with a dosage of 1-4 mg PO/IV/IM every 4-8 hours 1, 2
Psychiatric consultation is recommended for evaluation, treatment, and long-term planning of alcohol abstinence in patients with liver dysfunction 1, 3
Inpatient treatment is indicated for patients with high levels of recent drinking, history of withdrawal seizures or delirium tremens, co-occurring serious medical or psychiatric illness, liver failure, or failure of outpatient treatment 1, 4, 5, 6, 7, 8

The American Association for the Study of Liver Diseases recommends baclofen as a first-line medication for promoting long-term abstinence in patients with liver dysfunction, with a 12-week course effectively maintaining abstinence by reducing alcohol craving 4, 5
Acamprosate reduces withdrawal effects and alcohol craving, and should be initiated 3-7 days after last alcohol consumption and after withdrawal symptoms resolve, with a dosage of 1,998 mg/day for patients ≥60 kg 2, 4, 5
Alcohol abstinence is the most important treatment for patients with alcoholic liver disease, as it improves survival, prognosis, and prevents progression to cirrhosis 4

Thiamine supplementation should be given before administering IV fluids containing glucose to prevent precipitating acute thiamine deficiency, with a dosage of 100-300 mg/day for 4-12 weeks 2, 7
Careful monitoring of vital signs and evaluation of comorbidities such as dehydration, electrolyte imbalance, renal failure, and gastrointestinal bleeding is essential 9